The Kadota Fund International Forum 2004–Clinical group consensus*

Figures & data

Figure 1. Methods for clinical application of hyperthermia.

Table I.  LEVEL I evidence from randomised trials showing significantly better results following combination of radiotherapy (RT), chemotherapy (CT), or RT plus CT with hyperthermia (HT), compared to the same treatment without HT. LHT, local HT; RHT, regional HT; WBHT, whole body HT; CR, complete response.

Ref no.	Tumour	Treatment	Patients (lesions)	endpoint	Effect with HT	Effect without HT
13, 14	Lymphnodes of head & neck tumours	RT +/− LHT	41 (44)	CR rate	83%	41%
				5-yr local control	69%	24%
				5-yr survival	53%	0%
15	Melanoma	RT +/− LHT	70 (138)	CR rate	62%	35%
				2-yr local control	46%	28%
16	Breast	RT +/− LHT	306	CR rate	59%	41%
17	Glioblastoma multiforme	RT +/− LHT postoperative	68	Median survival	85 weeks	76 weeks
				2-yr survival	31%	15%
18	Bladder, cervix and rectum	RT +/− LHT	298	CR rate	55%	39%
				3-yr survival	30%	24%
18	Cervix	RT +/− LHT	114	CR rate	83%	57%
				3-yr survival	51%	27%
19	Rectum	RT +/− LHT preoperative	115	5-yr survival	36%	7%
20	Cervix	RT +/− LHT	64	CR	55%	31%
21	Various superficial	RT +/− LHT	92	Response	82%	63%
22	Cervix	RT +/− LHT	40	CR	85%	50%
23	Rectum	RT +/− LHT	14	Response	100%	20%
24	Bladder	RT +/− LHT preoperative	102	3-yr survival	94%	67%
25	Oesophagus	RT +/− LHT	125	3-yr survival	42%	24%
26	Rectum	RT +/− LHT preoperative	122	pCR	23%	5%
27	Bladder	CT +/− RHT preoperative	52	pCR	66%	22%
28	Bladder	CT +/− RHT postoperative		2-yr relapse free survival	∼82%	∼38%
29	Lung	CT +/− WBHT	44	Response	68%	36%
30	Soft tissue sarcoma	CT +/− LHT	341	Response	28.7%	12.6%
				Local relapse free survival	45.3 months	23.7 months
				Disease free survival	31.7 months	16.2 months
31	Oesophagus	RT + CT +/− LHT	66	CR	25%	6%
32	Oesophagus	RT + CT +/− LHT preoperative	53	Palliation	70%	8%